Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients

被引：28

作者：

Rocio, Carolina ^{[1
]}

Amato, Valdir Sabbaga ^{[1
]}

Camargo, Raphael A. ^{[1
]}

Tuon, Felipe F. ^{[2
]}

Nicodemo, Antonio Carlos ^{[1
]}

机构：

[1] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil

[2] Univ Fed Parana, Clin Univ Hosp, Div Infect Dis, BR-80060000 Curitiba, PR, Brazil

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2014年 / 108卷 / 03期

关键词：

Amphotericin B; Leishmania treatment; Leishmaniasis;

D O I：

10.1093/trstmh/tru011

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background: Studies assessing the efficacy of liposomal amphotericin B (LAB) in the treatment of patients with mucosal leishmaniasis (ML) are very scarce in the literature and an optimal dose regimen has not yet been defined. Methods: We performed a retrospective and descriptive analysis from records of 16 patients with ML treated with LAB. The mean daily dose of LAB was 2.5 mg/kg/day. Results: Healing of the lesion was observed in 14 (88%) of the 16 patients. The mean cumulative doses, excluding the two treatment failures, were 2265 mg and 33 mg/kg. Conclusion: Liposomal amphotericin B in the cumulative dose of 30 to 35 mg/kg was able to achieve 100% effectiveness.

引用

页码：176 / 178

页数：3

共 50 条

[1] Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B
Amato, Valdir Sabbaga
Tuon, Felipe Francisco
Campos, Aleia
Bacha, Helio Arthur
Nicodemo, Antonio Carlos
Neto, Vicente Amato
Shikanai-Yasuda, Maria Aparecida
CLINICAL INFECTIOUS DISEASES, 2007, 44 (02) : 311 - 312
[2] Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
Jaafari, Mahmoud Reza
Hatamipour, Mahdi
Alavizadeh, Seyedeh Hoda
Abbasi, Azam
Saberi, Zahra
Rafati, Sima
Taslimi, Yasaman
Mohammadi, Akram Miramin
Khamesipour, Ali
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2019, 11 : 156 - 165
[3] Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients
Minodier, P
Retornaz, K
Horelt, A
Garnier, JM
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (02) : 183 - 188
[4] Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients
Vigna, E.
De Vivo, A.
Gentile, M.
Morelli, R.
Lucia, E.
Mazzone, C.
Recchia, A. G.
Vianelli, N.
Morabito, F.
TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (05) : 428 - 431
[5] Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B
Machado, Paulo R. L.
Rosa, Maria Elisa A.
Guimaraes, Luis H.
Prates, Fernanda V. O.
Queiroz, Adriano
Schriefer, Albert
Carvalho, Edgar M.
CLINICAL INFECTIOUS DISEASES, 2015, 61 (06) : 945 - 949
[6] Liposomal amphotericin B as a treatment for human leishmaniasis
Balasegaram, Manica
Ritmeijer, Koert
Lima, Maria Angeles
Burza, Sakib
Genovese, Gemma Ortiz
Milani, Barbara
Gaspani, Sara
Potet, Julien
Chappuis, Francois
EXPERT OPINION ON EMERGING DRUGS, 2012, 17 (04) : 493 - 510
[7] Treatment of cutaneous leishmaniasis with liposomal amphotericin B
del Rosal Rabes, T.
Baquero-Artigao, F.
Gomez Fernandez, C.
Garcia Miguel, M. J.
de Lucas Laguna, R.
ANALES DE PEDIATRIA, 2010, 73 (02): : 101 - 102
[8] Liposomal amphotericin B for the treatment of visceral leishmaniasis
Bern, Caryn
Adler-Moore, Jill
Berenguer, Juan
Boelaert, Marleen
den Boer, Margriet
Davidson, Robert N.
Figueras, Concepcion
Gradoni, Luigi
Kafetzis, Dimitris A.
Ritmeijer, Koert
Rosenthal, Eric
Royce, Catherine
Russo, Rosario
Sundar, Shyam
Alvar, Jorge
CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) : 917 - 924
[9] Treatment of visceral leishmaniasis with liposomal amphotericin B
不详
HOSPITAL MEDICINE, 2001, 62 (09): : 577 - 577
[10] Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)
Russo, R
Nigro, LC
Minniti, S
Montineri, A
Gradoni, L
Caldeira, L
Davidson, RN
JOURNAL OF INFECTION, 1996, 32 (02) : 133 - 137

← 1 2 3 4 5 →